

03-11-2008



103487746

Our Ref.: LCM-3781-14

P.

To the Director of the U.S. Patent and Trademark Office, documents or copy thereof.


<p>1. Name of conveying party(ies): 1 Arana Therapeutics Limited 5 2 6 3 7 4 8</p> <p>Additional name/s of conveying party/ies attached? <input type="checkbox"/></p> <p>3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Assignment <input type="checkbox"/> Change of Name <input type="checkbox"/> Other</p> <p>Execution Date: <u>January 16, 2008</u></p>	<p>2. Name and address of receiving party(ies):</p> <p>1) Name: <u>Peptech Animal Health PTY Limited</u> Street Address: <u>19-25 Khartoum Road, Macquarie Park</u> City: <u>New South Wales</u></p> <p>State/Country: <u>Australia</u> Zip: <u>2113</u></p> <p>2) Name Street Address: City: State: Zip:</p> <p>Additional name/s & address/es attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
--	--

<p>4. Application number(s) or patent number(s): <input type="checkbox"/> This assignment is being filed together with a new application.</p> <p>A. Patent Application No(s). (1) <u>09/743,059</u> (2) (3)</p>	<p>B. Patent No(s). (1) <u>6,913,761</u> (2) (3)</p> <p>Additional numbers attached <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
--	--

<p>5. Name and address of party to whom correspondence concerning document should be mailed:</p> <p>Name: <u>Leonard C. Mitchard</u></p> <p>Internal Address:</p> <p>Street Address: <u>Nixon & Vanderhye P.C.</u> <u>901 North Glebe Road</u> <u>11th Floor</u></p> <p>City: <u>Arlington</u> State: <u>VA</u> Zip: <u>22203</u></p>	<p>6. Total number of applications & patents involved: <u>1</u></p> <p>7. Total fee (37 CFR 3.41) \$ <u>40.00</u> <input checked="" type="checkbox"/> Enclosed <input type="checkbox"/> Authorized to be charged to deposit account #14-1140</p> <p>8. The Commissioner is hereby authorized to charge any <u>deficiency</u> in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper thereafter filed in this application by this firm) to our Account No. 14-1140.</p>
---	--

DO NOT USE THIS SPACE

9. Statements and signature.
 To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

<p><u>Leonard C. Mitchard</u> Name of Person Signing Reg. No. 29,009</p>	 <p>Signature</p>	<p><u>March 6, 2008</u> Date</p>
--	---	---

Total number of pages including **original** cover sheet, attachments, and document: [4]

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

03/10/2008 MJAMA1 00000008 09743059
01 FC:0021 40.00 0P

DEED OF ASSIGNMENT made effective this 16 day of January... 2008

BETWEEN:

ARANA THERAPEUTICS LIMITED (ACN 002 951 877)

(formerly known as Peptech Limited)

of Level 2, 37 Epping Road, Macquarie Park, New South Wales, 2113, Australia

(hereinafter referred to as "the Assignor") of the one part

AND:

PEPTECH ANIMAL HEALTH PTY LIMITED (ACN 071 505 130)

of 19-25 Khartoum Road, Macquarie Park, New South Wales, 2113, Australia

(hereinafter referred to as "the Assignee") of the other part

WHEREAS

- i) The Assignor is the owner of the patents and patent applications identified in the schedule annexed hereto (hereinafter "the intellectual property"), and,
- ii) The Assignor and the Assignee have agreed to effect the transfer of the interest of the Assignor in the intellectual property to the Assignee pursuant to the terms of this Deed,

NOW THIS DEED WITNESSETH as follows:

In consideration of the sum of \$1 and other good and valuable consideration paid by the Assignee to the Assignor, receipt of which the Assignor acknowledges, the Assignor hereby transfers and assigns to the Assignee absolutely all of its right, title and interest in and to the intellectual property and the full benefit and advantage thereof, and the Assignee hereby accepts the assignment of that right, title and interest and the full benefit and advantage thereof.

IN WITNESS WHEREOF the parties hereto have caused this Deed to be executed as of the date hereinbefore mentioned.

SIGNED for and on behalf of
ARANA THERAPEUTICS LIMITED
by its duly authorised representative in the presence of

Niall

Signature of authorised representative

NIALL HENDERSON

Name of authorised representative

[Signature]

Signature of Witness

**RON
KAL**

Name of Witness

SIGNED for and on behalf of
PEPTECH ANIMAL HEALTH PTY LIMITED
by its duly authorised representative in the presence of

Niall

Signature of authorised representative

NIALL HENDERSON

Name of authorised representative

[Signature]

Signature of Witness

**RON
KAL**

Name of Witness

SCHEDULE

Application/Patent No.	Title	Country
713413	Sustained peptide-release formulation	Australia
2264562	Sustained peptide-release formulation	Canada
ZL97197548.5	Sustained peptide-release formulation	China
1007080	Formulation for the sustained release of peptide agonists and analogues of GnRH	Europe (Validated in BE, CH/LI, DE, DK, ES, FR, GB, IE, IT, LU, MC, NL, SE)
HK1022275	Sustained peptide-release formulation	Hong Kong
3860841	Sustained peptide-release formulation	Japan
334236	Sustained peptide-release formulation	New Zealand
6777386	Sustained peptide-release formulation	United States of America
10/808504	Sustained peptide-release formulation	United States of America
6337318	Sustained GNRH peptide-release formulation	United States of America
755443	Bioimplant formulation	Australia
9912275-8	Bioimplant formulation	Brazil
2336879	Bioimplant formulation	Canada
ZL99808961.3	Bioimplant formulation	China
200510097821.2	Bioimplant formulation	China
99932545.9	Bioimplant formulation	Europe
01104686.0	Bioimplant formulation	Hong Kong
2000-560890	Bioimplant formulation	Japan
234315	Bioimplant formulation	Mexico
6913761	Bioimplant formulation	United States of America
11/041270	Bioimplant formulation	United States of America
11/727655	Bioimplant formulation	United States of America
2001/0567	Bioimplant formulation	South Africa
701837	Novel formulation for peptide release	Australia
2225796	Novel formulation for peptide release	Canada
ZL96194864.7	Novel formulation for peptide release	China
18438/99	Novel formulation for peptide release	Australia
0871467	Formulation for peptide release	Europe (Validated in AT, BE, CH/LI, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
HK1014874	Novel formulation for peptide release	Hong Kong
09-503457	Novel formulation for peptide release	Japan
309697	Novel formulation for peptide release	New Zealand
5925619	Formulation for peptide release	United States of America
659508	Biocompatible implant for the timing of ovulation in mares	Australia
2121674	Biocompatible implant for the timing of ovulation in mares	Canada
69230040	Biocompatible implant for the timing of ovulation in mares	Germany
0609345	Biocompatible implant for the timing of ovulation in mares	Europe (Validated in AT, BE, CH/LI, DE, ES, FR, GB, IE, IT, SE)
3313113	Biocompatible implant for the timing of ovulation in mares	Japan
5545408	Biocompatible implant for the timing of ovulation in mares	United States of America

PATENT

RECORDED: 03/06/2008

REEL: 020627 FRAME: 0811